HealthTech Arkansas, a healthcare accelerator and investment fund that connects early-stage healthcare companies with disruptive technologies to Arkansas healthcare providers, has selected BardyDx to participate in its 2019 accelerator programme. BardyDx was chosen for its carnation ambulatory monitor (CAM)—the industry’s only P-wave centric ambulatory cardiac patch monitor and arrhythmia detection device.
HealthTech Arkansas is a new and expanded iteration of two previous accelerator programmes in the state, Health InnovatAR and HubX-LifeSciences. This year, with more provider partners and increased investment for participating companies, HealthTech Arkansas is focused on bringing the most innovative healthcare technologies to Arkansas.
This year’s six companies were selected from hundreds of applicants across 18 different countries. The cohort will participate in a programme that provides them the opportunity to partner with and build solutions specifically identified by Arkansas Heart Hospital, Arkansas Children’s, Arkansas Urology, Baptist Health, CHI St. Vincent, Conway Regional, Mercy, the University of Arkansas for Medical Sciences (UAMS), and Washington Regional Medical Center as areas of opportunity within their organisations. Each of the cohort companies will receive seed investment as well as complete and total access to clinicians and administrators at each partnering site.
Ken Nelson, BardyDx chief commercial officer, says: “It is an honour to be selected as part of the 2019 accelerator cohort. HealthTech Arkansas presents an invaluable opportunity to perform clinical studies with highly-engaged and pioneering healthcare organisations that are eager to implement the newest innovative technologies, like the CAM patch, to advance their clinical care—a clear win for both BardyDx and each partnering institution.”
Jeff Stinson, director of HealthTech Arkansas, says: “We are delighted to have the participation of BardyDx as one of six companies in our cohort this year. Collectively, they’re among the most accomplished early stage healthcare companies in the country. BardyDx was specifically chosen because the leadership teams in our partner hospitals believe the company can significantly increase the quality of care through its innovative devices. We cannott wait to begin our work with BardyDx.”
A press release reports that this distinction adds to the growing market recognition of the innovative P-wave centric CAM patch. Recently, BardyDx was named both the winner of the 2019 MedTech Breakthrough Award for Best New Diagnostic Technology and the winner of the 2019 Frost & Sullivan Award for Technology Innovation in Remote Cardiac Monitoring. Also, BardyDx was recently named the winner of the Impact Pediatric Health Competition hosted by the USA’s leading paediatric healthcare institutions at SXSW 2019 for the CAM’s unique paediatric-friendly design and potential to address significant unmet needs in paediatric healthcare. Additionally, BardyDx was also selected as the winner of the 2018 Fierce Innovation Life Sciences Award for Medical Device Innovation from the leading industry publisher of FierceBiotech & FiercePharma.
For the five other startup companies selected in the programme, click here
